
## Redefining cardiopulmonary care with Al informed by science, inspired by care.



Harnessing multimodal intelligence to advance diagnosis and patient monitoring — empowering clinicians to deliver smarter, more personalized care.



Cardiopulmonary diseases are the leading cause of death worldwide - more than 20 million in 2022. In Switzerland, they account for nearly 30% of all deaths. While early detection is key in reducing these numbers, it remains a major challenge in clinical practice — leaving many patients without the chance of a better treatment.



Based on our research in medical AI at ETH Zurich, and close collaboration with medical doctors, we believe it's time to change this. We are building Paracelsus Health Intelligence to redefine how clinical decisions are made.

By combining all available data, the medical Al Agent builds a holistic view of the patient. It acts both as a personalised early detection system, and as an assistant that collaborates with clinicians providing data-driven insights.

We're not just building another AI tool — we're laying the foundation for a future where every clinical decision is informed by the full richness of patient data, delivering better care at lower cost.

Team: Andrea Agostini, Julia Spiess, Chiara Ballinari, Julian Heidenreich, Gabriela Myburgh, Thomas Sutte

Contact: t.sutter@me.com





